From: In silico evaluation of some 4-(quinolin-2-yl)pyrimidin-2-amine derivatives as potent V600E-BRAF inhibitors with pharmacokinetics ADMET and drug-likeness predictions
SN
Lipinski
Ghose
Veber
Egan
Muegge
Synthetic accessibility
5
0
1
2.91
9
3.13
10
3.06
11
3.2
Vem.
2
3.38